Webcasts: AABB New Orleans 2009 Workshop

Establishing the Safety and Efficacy
of Pathogen Inactivation
The role of powered clinical studies for medical
device development in transfusion medicine Presented on Friday, October 27 • New Orleans, LA
In association with the AABB Annual Meeting & TXPO 2009
Overview
A growing number of blood centers in Europe and the Middle East are converting their routine
component production to include universal pathogen inactivation (PI) of platelets and plasma.
In order to meet customer needs for operational ease of use and regulatory compliance, PI
technologies must offer processing flexibility and broad platform compatibility. This symposium
examines customer experiences with the INTERCEPT Blood System, as well as new developments
in progress.
Speaker Profiles

Larry Dumont, MBA, PhD
Assistant Professor of Pathology, Dartmouth Medical School, USA

Larry received his BS in Biology at Regis College, Denver, and MBA from
the University of Phoenix. He was awarded a PhD in Clinical Sciences
at the University of Colorado Health Sciences Center in Denver where
he received training in biostatistics and epidemiology. He has four years
clinical background in Pediatric Dialysis at the University of Colorado.
Larry spent 25 years with COBE Laboratories / Gambro BCT as an
engineer and manager in Quality Assurance and as a scientist in R&D.
In the latter position he was the project leader for 7-day platelets and the
PASSPORT Study. Currently, Larry is Assistant Professor of Pathology at
Dartmouth Medical School and Director of the Cell Labeling Laboratory.
He has extensive experience in experimental design and data analysis
both in the industrial and clinical settings. His current interests are in
platelet physiology, in vivo cell survival kinetics, and clinical outcomes in
transfusion medicine.

Laurence Corash, MD
Chief Medical Offi cer, Cerus Corporation, USA
Professor of Laboratory Medicine, University of California San
Francisco, USA

Dr. Corash graduated from New York University School of Medicine and
completed Internal Medicine training at Bellevue Hospital, New York,
NY. From 1971 to 1973 he was a Research Associate at the National
Institute of Child Health and Human Development (NICHD), Bethesda,
MD; and completed training in Hematology and Hematopathology at the
National Institutes of Health (NIH), Clinical Center, Bethedsa, MD. From
1977 to 1981 he served as Assistant Chief, Hematology Service, Clinical Center, NIH. From 1982 to 1997 Dr. Corash was Chief of the Hematology Laboratory Service at the University of California, San Francisco and a member of the faculty in Medicine and Laboratory Medicine. His research activities include blood cell aging and technology for inactivation of infectious pathogens in blood components. He has published more than 150 basic research papers in the broad fi eld of hematology and transfusion medicine. Over the past 10 years, Dr. Corash has directed a research team in the development of technology for the inactivation of pathogens in labile blood components. The system for preparation of platelets received European Community CE Mark registration in 2002.

Miguel Lozano, MD, PhD
Acting Chief, Hemotherapy Section, Hospital Clinic Barcelona, Spain

Miguel Lozano, MD, PhD received his medical degree from the University of Barcelona School of Medicine with outstanding award recognition. He completed his residency in Hematology and Hemotherapy at the Clínic University Hospital and a research fellowship at the Utrecht University Hospital, the Netherlands, ultimately obtaining his PhD in Medicine and Surgery, with honors, from the University of Barcelona.

Dr. Lozano is a member of 10 national and international professional
societies, for which he has served on several committees. Previously,
he has served as President of the Catalan Society of Blood Transfusion,
Vice President of the Spanish Society of Blood Transfusion and as a
member of the Hemovigilance Committee of the Catalan Health Service.
He is currently Chair of the AABB Press Editorial Board, and serves on
the Scientifi c Committee for Transfusion Safety of the Spanish Ministry
of Health. In addition, Dr. Lozano is the Spanish representative for the
Council of Europe Committee of Experts on Quality Assurance in Blood
Transfusion Services.

Dr. Lozano is the author or co-author of over 100 papers, monographs and book chapters dealing with topics related with Transfusion Medicine. He has co-edited a book for AABB Press about Globalization in Transfusion Medicine and a book about Pathogen Inactivation of blood components.